Cardiometabolic Effects of Pecan Snacking in Prediabetes

N/ANot Yet RecruitingNCT07235358

Penn State University147 enrolled

Overview

The purpose of this study is to investigate the effects of replacing snacks higher in saturated fats and added sugars with pecans on blood sugar control, heart health and diet quality in individuals with prediabetes. Participants will be randomized into one of two groups. Group 1 will consume 1.5 oz of pecans per day in place of normally consumed snacks higher in saturated fat and added sugars for 16 weeks. Group 2 will be asked to continue consuming their current diet for 16 weeks. Measures will be taken to evaluate blood sugar, heart health and dietary intake at the beginning and 16 weeks later.

This is a 16-week randomized controlled trial. Participants will be randomized to either: 1) replace current snacks higher in saturated fat and added sugars with 1.5 oz/day of pecans; 2) continue their habitual diet. At the beginning and the end of the 16-week study period, testing will be conducted.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

SINGLE

Enrollment

147

Conditions

Prediabetes

Interventions

Pecan snackingBEHAVIORAL

Replacement of typically consumed snacks with 1.5 oz/day of pecans

Usual dietOTHER

Continue with usual diet

Eligibility

Sex: ALLMin age: 25 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age 25-65 years * Prediabetes assessed by an HbA1c of 5.7-6.4% at screening * BMI 25-40 kg/m2 at screening * Low habitual nut consumption (\<3.5 oz-eq/week) assessed at the telephone screening * Regularly eats snacks higher in saturated fat and/or added sugars assessed at the telephone screening Exclusion Criteria: * LDL-C ≥190 mg/dL at screening * Hemoglobin \<13.2 g/dL at screening * Fasting triglycerides \>350 mg/dL at screening * ≥10% change in body weight within the 6 months prior to enrollment * Blood pressure \>140/90 mmHg at screening * Type 1 or type 2 diabetes * Prescription of anti-hypertensive, lipid-lowering, or glucose-lowering drugs * Intake of supplements or over-the-counter medications that affect the outcomes of interest (i.e., lipid, blood pressure, or glucose lowering; vitamin C or multi-vitamins containing vitamin C) and are unwilling to cease during the study period. * History of liver, kidney, or autoimmune disease * Prior cardiovascular event (e.g., stroke, heart attack) * Current pregnancy or intention of pregnancy within the next 12 months * Lactation within the prior 6 months * Pecan allergy/intolerance/sensitivity/dislike * Unwilling/unable to eat 1.5 oz of pecans every day as a snack during the duration of the study * Antibiotic use within the prior 4 weeks * Oral steroid use within the prior 4 weeks * Use of tobacco or nicotine-containing products within the past 6 months * History of cancer at any site within the past 10 years (eligible if ≥10 years without recurrence) or non-melanoma skin cancer within the past 5 years (eligible if ≥5 years without recurrence) * Participation in another clinical trial within 60 days of baseline * Unwilling to contact study staff before enrolling in other health-related research and avoid participating in any research that may interfere with this study. * Currently following a restricted or weight-loss diet * Prior bariatric surgery * Intake of \>14 alcoholic drinks/week and/or not willing to avoid alcohol consumption for 48 hours prior to test visits * Principal Investigator discretion related to the potential participant's ability to adhere to the study requirements, including being able to come to attend visits * Does not speak and/or understand English * Unwilling to refrain from donating blood or plasma during the study * Weight \<110 lb * If a potential participant takes thyroid medicine, abnormal thyroid stimulated hormone (TSH) concentration (TSH outside of normal range), or change in dose of thyroid medication within the last 6 months

Outcomes

Primary Outcomes

Change in HbA1c

HbA1c will be assessed at baseline and 16-weeks and expressed as percentage . The change in HbA1c will be calculated by subtracting the baseline value from the 16 week value and expressed as percentage point change.

Time frame: 16 weeks

Secondary Outcomes

Change in fasting glucose

Change in fasting plasma glucose expressed as mg/dL. Change in glucose will be calculated as the mean of the 16 week measures (i.e., mean of day 1 and day 2 values) minus the mean of the baseline measures (i.e., mean of day 1 and day 2 values).

Time frame: 16 weeks

Change in mean glucose

Change in mean glucose assessed by a continuous glucose monitor (CGM) expressed as mg/dL. Change in mean glucose will be calculated as mean glucose assessed from 7 days of CGM wear at 16 weeks minus mean glucose assessed from 7 days of CGM wear at baseline.

Time frame: 16 weeks

Change in mean time in range

Change in mean time in range (glucose 70-140 mg/dL) assessed by a continuous glucose monitor (CGM) expressed as minutes per day. Change in mean time in range will be calculated as mean time in range assessed from 7 days of CGM wear at 16 weeks minus mean time in range assessed from 7 days of CGM wear at baseline.

Time frame: 16 weeks

Change in glycemic variability

Change in mean glycemic variability assessed by a continuous glucose monitor (CGM) expressed as the coefficient of variability. Change in mean glycemic variability will be calculated as mean glycemic variability assessed from 7 days of CGM wear at 16 weeks minus mean glycemic variability assessed from 7 days of CGM wear at baseline.

Time frame: 16 weeks

Change in fasting insulin

Central Contacts

Kristina Petersen, PhD

CONTACT

814-865-7206 kup63@psu.edu

Stacey Meily

CONTACT

814-863-8622 sas117@psu.edu

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Change in fasting serum insulin expressed as micro IU/mL. Change in insulin will be calculated as the mean of the 16 week measures (i.e., mean of day 1 and day 2 values) minus the mean of the baseline measures (i.e., mean of day 1 and day 2 values).

Time frame: 16 weeks

Change in homeostatic model of insulin resistance (HOMA-IR)

Homeostatic model of insulin resistance (HOMA-IR) will be calculated from insulin and glucose measured from a fasting blood sample. Calculated as (insulin × glucose) / 22.5. Change in HOMA-IR will be calculated as the mean of the 16 week measures (i.e., mean of day 1 and day 2 values) minus the mean of the baseline measures (i.e., mean of day 1 and day 2 values).

Time frame: 16 weeks

Change in the lipoprotein insulin resistance index

The lipoprotein insulin resistance index will be calculated from Nuclear Magnetic Resonance assessed lipoprotein concentrations according to a previously described method: Metab, Syndr. Relat. Disord. 12 (8) (2014) 422-429. Change will be calculated by subtracting the baseline value from the 16 week value.

Time frame: 16 weeks

Change in LDL-Cholesterol

Assessed from fasting blood draw expressed in mg/dL. Change in LDL-cholesterol will be calculated as the mean of the 16-week measures (i.e., mean of day 1 and day 2 values) minus the mean of the baseline measures (i.e., mean of day 1 and day 2 values).

Time frame: 16 weeks

Change in apolipoprotein B

Assessed from fasting blood draw expressed in mg/dL. Change in apolipoprotein B will be calculated by subtracting the baseline value from the 16 week value.

Time frame: 16 weeks

Change in non-HDL cholesterol

Assessed from fasting blood draw expressed in mg/dL. Change in non-HDL cholesterol will be calculated as the mean of the 16-week measures (i.e., mean of day 1 and day 2 values) minus the mean of the baseline measures (i.e., mean of day 1 and day 2 values).

Time frame: 16 weeks

Change in Total Cholesterol

Assessed from fasting blood draw expressed in mg/dL. Change in total cholesterol will be calculated as the mean of the 16-week measures (i.e., mean of day 1 and day 2 values) minus the mean of the baseline measures (i.e., mean of day 1 and day 2 values).

Time frame: 16 weeks

Change in HDL-Cholesterol

Assessed from fasting blood draw expressed in mg/dL. Change in HDL-cholesterol will be calculated as the mean of the 16-week measures (i.e., mean of day 1 and day 2 values) minus the mean of the baseline measures (i.e., mean of day 1 and day 2 values).

Time frame: 16 weeks

Change in Triglycerides

Assessed from fasting blood draw expressed in mg/dL. Change in triglycerides will be calculated as the mean of the 16-week measures (i.e., mean of day 1 and day 2 values) minus the mean of the baseline measures (i.e., mean of day 1 and day 2 values).

Time frame: 16 weeks

Change in C-reactive protein

Assessed from fasting blood draw expressed in mg/L. Change in C-reactive protein will be calculated as the mean of the 16-week measures (i.e., mean of day 1 and day 2 values) minus the mean of the baseline measures (i.e., mean of day 1 and day 2 values).

Time frame: 16 weeks

Change in Central Systolic and Diastolic Blood Pressure

Central blood pressure measured assessed using a SphymoCor Xcel (Atcor Medical) at baseline \& 16 weeks. Change will be calculated by subtracting the baseline value from the end point value.

Time frame: 16 weeks

Change in Peripheral Systolic and Diastolic Blood Pressure

Peripheral blood pressure measured assessed using a SphymoCor Xcel (Atcor Medical) at baseline \& 16 weeks. Change will be calculated by subtracting the baseline value from the end point value.

Time frame: 16 weeks

Change in Carotid-Femoral Pulse Wave Velocity

Measured assessed using a SphymoCor Xcel (Atcor Medical) at baseline \& 16 weeks. Change will be calculated by subtracting the baseline value from the end point value.

Time frame: 16 weeks

Change in particle size and number of LDL, HDL, triglyceride rich lipoproteins

Measured via Nuclear Magnetic Resonance at baseline and 16 weeks. The change will be calculated by subtracting the baseline value from the 16 week value.

Time frame: 16 weeks

Change in Saturated fat intake

Assessed from 24-hour recalls completed prior to baseline and at 16 weeks. Change in saturated fat will be calculated as saturated fat intake at 16 weeks minus baseline saturated fat intake.

Time frame: 16 weeks

Change in added sugar intake

Assessed from 24-hour recalls completed prior to baseline and at 16 weeks. Change in added sugar intake will be calculated as added sugar intake at 16 weeks minus baseline added sugar intake.

Time frame: 16 weeks

Change in diet quality

Assessed from 24-hour recalls completed prior to baseline and at 16 weeks. Diet quality will be calculated according to the Healthy Eating Index-2020 (HEI). Change in HEI will be calculated as HEI at 16 weeks minus baseline HEI.

Time frame: 16 weeks